BW-A78U

CAS No. 101155-02-6

BW-A78U( —— )

Catalog No. M19920 CAS No. 101155-02-6

BW-A 78U is a PDE4 inhibitor (IC50: 3 μM). It is not inhibition on the lipopolysaccharide (LPS)-induced TNF-α release.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 35 In Stock
5MG 98 In Stock
10MG 147 In Stock
25MG 249 In Stock
50MG 351 In Stock
100MG 496 In Stock
200MG 681 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    BW-A78U
  • Note
    Research use only, not for human use.
  • Brief Description
    BW-A 78U is a PDE4 inhibitor (IC50: 3 μM). It is not inhibition on the lipopolysaccharide (LPS)-induced TNF-α release.
  • Description
    BW-A 78U is a PDE4 inhibitor (IC50: 3 μM). It is not inhibition on the lipopolysaccharide (LPS)-induced TNF-α release.
  • In Vitro
    BW-A 78U is a PDE4 inhibitor with an IC50 of 3 μM. BW-A 78U fails to significantly inhibit arachidonate release.BW-A 78U is ineffective to inhibit the lipopolysaccharide (LPS)-induced TNF-α release.
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Angiogenesis
  • Target
    PDE
  • Recptor
    PDE4
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    101155-02-6
  • Formula Weight
    257.27
  • Molecular Formula
    C13H12FN5
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO: 100 mg/mL
  • SMILES
    CNc1ncnc2n(Cc3ccccc3F)cnc12
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Boichot E et al. Anti-inflammatory activities of a new series of selective phosphodiesterase 4 inhibitors derivedfrom 9-benzyladenine. J Pharmacol Exp Ther. 2000 Feb;292(2):647-53.
molnova catalog
related products
  • Cilostamide

    Cilostamide is a selective phosphodiesterase (PDE)3A and PDE3B inhibitor(IC50 values of 27 and 50 nM respectively).

  • Verofylline

    Verofylline (Verofyllinum) is an orally available, long-acting, multiacting, methylxanthine-substituted bronchodilator with inhibitory effects on PDE4 for the treatment of asthma disease research obesity.

  • HA-155

    HA155 is a boronic acid-based compound, inhibiting ATX with IC50 of 5.7 nM by selectively binding to its catalytic threonine.